Jump to content
Sclero Forums

GocartMoz

Members
  • Content count

    175
  • Joined

  • Last visited

About GocartMoz

  • Rank
    Silver Member

Profile Information

  • Location
    Florida
  1. Prospective long-term follow-up of patients localised Wegener's granulomatosis (locWG): does it occur as persistent disease stage? There is evidence that locWG is a long-term disease stage or phenotype (5% of all patients with WG), 46% of whom are ANCA-positive. LocWG is characterised by destructive and/or space-consuming lesions associated with high relapse rates (46%) and local damage. J U Holle. Ann rheumatologist Dis.May 2010. (Also see: Wegener's Granulmatosis) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  2. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis. Cell-mediated responses to influenza vaccination in patients with WG are comparable to those in healthy controls. Albert Holvast. Ann rheumatologist Dis 2010;69:924-927. (Also see: Wegener's Granulmatosis) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  3. Women’s experience of SLE-related fatigue: a focus group interview study. SLE-related fatigue was portrayed as an overwhelming phenomenon with an unpredictable character, resulting in the feeling that fatigue dominates and controls most situations in life. S. Pettersson. Rheumatology Advance Access. June 23 2010. (Also see: Lupus Symptoms) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  4. Treatment of patients with destructive arthritis with certolizumab pegol. Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol. (SpringerLink) T. Schmeiser. Zeitschrift fur Rheumatologie. June 9 2010. (Also see: Treatments for RAand TNF Inhibitors) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  5. Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus. Significant clinical improvement of the subacute cutaneous lupus erythematosus lesions was achieved in all patients, with four patients in complete remission and two in partial remission. (SageJournals) A. Raptopoulou. Lupus. May 1 2010. (Also see: Treatments for Lupus) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  6. Secondary Sjögren's Syndrome (SS) in Systemic Lupus Erythematosus (SLE) Defines a Distinct Disease Subset. The subset of patients with SLE and SS has a distinct clinical and laboratory phenotype, with a higher frequency of older white women with photosensitivity, oral ulcers, Raynaud’s phenomenon, anti-Ro antibodies, and anti-La antibodies and a lower frequency of renal disease, anti-dsDNA antibodies, and anti-RNP antibodies. A. Baer. JRheum. April 1 2010. (Also see: Lupus and Overlapping Diseases and Sjögren's) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  7. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. We report the case of a psoriasis patient who developed pulmonary sarcoidosis during a cycle of therapy with infliximab. S. Izzi. Dermatology Online Journal. May 2010. (Also see: Causes of Sarcoidosis) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  8. Management of Rheumatic Diseases During Pregnancy. Recent data suggest that increased disease activity in women with most autoimmune diseases during pregnancy may lead to increased risk of premature delivery, low-birth-weight infants, and other adverse pregnancy outcomes. A.B. Elliott, M.D. Postgraduate Medicine: Volume 122: No.3. (Also see: Scleroderma and Pregnancy) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  9. Possible Detrimental Effects of Cognitive Behaviour Therapy (CBT) for Chronic Fatigue Syndrome (CFS). CBT is not only a helpful, but also a safe treatment for CFS. (Karger) M.J. Heins. Psychotherapy and Psychosomatics. Vol. 79, No. 4, 2010. (Also see:CFS) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  10. Male-only Systemic Lupus (SLE). Because women in the all-male families had positive antinuclear antibodies, and men are more likely to have children with SLE, these data suggest genetic susceptibility factors that act only in men. R. Aggarwal. Journal of Rheumatology. May 15, 2010. (Also see: Lupus and Genetics) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  11. Epstein–Barr virus (EBV) -associated infectious mononucleosis (IM) and risk of systemic lupus erythematosus (SLE). EBV-associated IM does not seem to be a risk factor for SLE. C.J. Ulff-Moller. Rheumatology Advance Access. May 20 2010. (Also see: Lupus and Overlapping Diseases) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  12. Central nervous system (CNS) involvement in Sjögren’s syndrome (pSS): unusual, but not unremarkable—clinical, serological characteristics and outcomes in a large cohort of Italian patients. CNS involvement represents a rare but not negligible complication of pSS. A. Massara. Rheumatology Advance Access. May 5 2010. (Also see: Symptoms of Sjogren's) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  13. Clinical manifestations of neurological involvement in primary Sjögren’s syndrome (pSS). Our observations suggest that a number of mechanisms can be attributed to neurological involvements in pSS rather than just the mechanisms previously described (i.e., vasculitis and ganglioneuronitis). Presumably, specific autoantibodies may directly induce injury of the nervous system. (SpringerLink) T. Gono. Clinical Rheumatology. April 15 2010. (Also see: Symptoms of Sjogren's) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  14. Impact of lupus (SLE) on school attendance and performance. SLE and activities related to caring for the disease clearly impose a burden on children’s school attendance and performance. School-related activities can have a significant impact on HRQOL in children and adolescents with SLE. Moorthy LN. (PubMed) Lupus. 2010;19(5):620-7. (Also see: Pediatric Lupus) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
  15. Access to Care and the Incidence of Endstage Renal Disease (ESRD) Due to Systemic Lupus Erythematosus (SLE). Persons with low socioeconomic status have an increased risk of ESRD due to SLE, possibly because of limited access to care. M. Ward. JRheum. April 15 2010. (Also see: Lupus Renal Involvement) This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
×